I8J-MC-JYCA - ClinicalTrials.gov - NCT02791334
I8J-MC-JYCA - ClinicalTrials.gov - NCT02791334
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology - Participants entering the Phase 1a dose escalation must submit, if available, an archival tumor tissue sample
Participants participating ONLY in the Phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (≤3 years since last documented progression of disease.) biopsy
Participants must NOT
Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids
Participant must not have a bowel obstruction or chronic diarrhea
Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
Participant must not have received a live vaccine within 30 days before the first dose of study treatment
Trial Summary
Conditions the trial is for
Solid Tumor, Lung Cancer
What the trial is testing?
LY3300054, Ramucirumab, Abemaciclib, Merestinib
Could I receive a Placebo?
no
Enrollment Goal
215
Trial Dates
June 2016 - December 2021
Trial Phase
1
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have diagnosis of advanced solid tumor confirmed by histology or cytology - Participants entering the Phase 1a dose escalation must submit, if available, an archival tumor tissue sample
Participants participating ONLY in the Phase 1b expansion must submit tissue sample from either a newly obtained core or excisional biopsy of a tumor lesion or a recent (≤3 years since last documented progression of disease.) biopsy
Participants must NOT
Participant must not have a serious concomitant systemic disorder including HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids
Participant must not have a bowel obstruction or chronic diarrhea
Participant must not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
Participant must not have received a live vaccine within 30 days before the first dose of study treatment
Trial Summary
Conditions the trial is for
Solid Tumor, Lung Cancer
What the trial is testing?
LY3300054, Ramucirumab, Abemaciclib, Merestinib
Could I receive a Placebo?
no
Enrollment Goal
215
Trial Dates
June 2016 - December 2021
Trial Phase
1
Trial Locations
Hide locations not currently recruiting